Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02631928|
Recruitment Status : Completed
First Posted : December 16, 2015
Last Update Posted : August 2, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus||Drug: human biphasic insulin Drug: human biphasic insulin, reference||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||73 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Single-center, Randomized, Double-blind, 2-treatment, 2-period Crossover Trial in Healthy Subjects to Demonstrate PK Bioequivalence and to Compare the PD Properties of Julphar Insulin 30/70 and Huminsulin® Profil III|
|Study Start Date :||February 2016|
|Actual Primary Completion Date :||June 2016|
|Actual Study Completion Date :||June 2016|
Experimental: Julphar Insulin 30/70
human biphasic insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
Drug: human biphasic insulin
investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
Other Name: Julphar Insulin 30/70
Active Comparator: Huminsulin® Profil III
human biphasic insulin, reference, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
Drug: human biphasic insulin, reference
marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
Other Name: Huminsulin® Profil III
- PK: AUCins.0-24, harea under the serum insulin concentration curve from 0-24 hours [ Time Frame: 24 hours ]
- PK: Cins.max, maximum observed insulin concentration [ Time Frame: 24 hours ]24 hours
- PK: AUCins.0-6h, AUCins.0-12, areas under the serum insulin concentration curve in the indicated time intervals [ Time Frame: 12 hours ]
- PK: AUCins.0-∞, area under the serum insulin concentration-time curve from 0 hours to infinity [ Time Frame: 24 hours ]
- PK: tmax, time to maximum observed serum insulin concentration [ Time Frame: 24 hours ]
- PK: t½, terminal serum elimination half-life calculated as t½=ln2/λz [ Time Frame: 24 hours ]
- PK: λz, terminal elimination rate constant of insulin [ Time Frame: 24 hours ]
- PD: AUCGIR.0h-last, area under the glucose infusion rate curve from 0 hours until the end of clamp [ Time Frame: 24 hours ]
- PD: GIRmax, maximum observed glucose infusion rate [ Time Frame: 24 hours ]
- PD: AUCGIR.0-6h, AUCGIR.0-12h, areas under the glucose infusion rate curve in the indicated time-intervals [ Time Frame: 12 hours ]
- PD: tGIR.max, time to maximum glucose infusion rate [ Time Frame: 24 hours ]
- PD: Onset of action, time from trial product administration until blood glucose concentration has decreased at least 5 mg/dL from baseline [ Time Frame: 24 hours ]baseline is defined as the mean of blood glucose levels from -6, -4, and -2 minutes before trial product administration as measured by the glucose clamp device
- Adverse events [ Time Frame: from the first trial drug administration until the final examination ]Through study completion, approx.up to approx. 39 days for each subject and up to 6 month for total study duration..
- Local tolerability findings [ Time Frame: dosing period, approx.up to 39 days for each subject ]
at the injection site. Through study completion,
The local tolerability at the injection site will be evaluated by means of the following assessments:
- spontaneous pain
- pain on palpation
- other Each of these assessments will be reported on a scale of 0 (none), 1 (mild), 2 (moderate) and 3 (severe). The evaluation and the actual time of the assessment will be recorded.
- Laboratory safety parameters [ Time Frame: from screening until final examination, approx.up to 60 days for each subject ]Including haematology, biochemistry and coagulation including serology (only at screening) parameters. Through study completion,
- Physical examination findings [ Time Frame: from screening until final examination, approx.up to 60 days for each subject ]Through study completion,
- Changes in vital signs [ Time Frame: from screening until final examination, approx.up to 39 days for each subject ]Through study completion,
- Changes in Electrocardiogram recordings [ Time Frame: from screening until final examination, approx.up to 60 days for each subject ]Through study completion,
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 55 Years (Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||Yes|
- Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedures that would not have been performed during normal management of the subject).
- Healthy male subject.
- Age between 18 and 55 years, both inclusive.
- Body Mass Index (BMI) between 18.5 and 28.0 kg/m^2, both inclusive.
- Fasting plasma glucose concentration <= 100 mg/dL.
- Known or suspected hypersensitivity to IMPs or related products.
- Previous participation in this trial. Participation is defined as randomised.
- Receipt of any medicinal product in clinical development within 3 months before screening.
- Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer as judged by the Investigator.
- Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness as judged by the Investigator.
- Surgery within 12 weeks before the start of the study or blood donation of more than 500 mL (or considerable blood loss) or plasma donation within the last 3 months.
- Increased risk of thrombosis, e.g., subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.
- Clinically significant abnormal values for haematology, biochemistry, coagulation, or urinalysis as judged by the Investigator.
- Supine blood pressure (BP) at screening (after resting for 5 minutes in a supine position) outside the range of 90 to 140 mmHg for systolic BP or 50 to 90 mmHg for diastolic BP (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial) and/or resting supine pulse < 50 beats per minute.
- Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator.
- Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety.
- Positive to the screening test for Hepatitis Bs antigen or Hepatitis C antibodies and/or a positive result to the test for HIV-1/2 antibodies or HIV-1 antigen.
- History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.
- Any medication (prescription and non-prescription drugs) within 14 days before first trial drug administration and/or anticoagulant therapy, with the exception of stable treatment with thyroid hormones, paracetamol and ibuprofen for occasional use to treat pain.
- Significant history of alcoholism or drug abuse as judged by the Investigator or consuming more than 21 units of alcohol per week (one unit of alcohol equals about 330 mL of beer, one glass of wine of 120 mL, or 40 mL spirits).
- A positive result in the alcohol and/or urine drug screen at the screening visit.
- Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) who is not able or willing to refrain from smoking and use of nicotine substitute products 1 day before and during the inpatient period.
- Subject with mental incapacity or language barriers precluding adequate understanding or cooperation or who, in the opinion of the Investigator, should not participate in the trial.
- Potentially noncompliant or uncooperative during the trial, as judged by the Investigator.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02631928
|Profil Institut für Stoffwechselforschung GmbH|
|Neuss, Germany, 41460|
|Principal Investigator:||Ulrike Hövelmann, MD||Profil Institut für Stoffwechselforschung GmbH|
|Responsible Party:||Julphar Gulf Pharmaceutical Industries|
|Other Study ID Numbers:||
2015-003993-34 ( EudraCT Number )
|First Posted:||December 16, 2015 Key Record Dates|
|Last Update Posted:||August 2, 2016|
|Last Verified:||August 2016|
biphasic human insulin
Insulin, Globin Zinc
Physiological Effects of Drugs